Summary:
In this podcast, first recorded at IO360º 2024, xperts in applying artificial intelligence for drug discovery and development take the audience ‘under the hood’ of artificial intelligence: where it’s the most useful in improving human tasks, how it’s leveraging data from patients in the clinic and where it’s making the impossible possible.
More specifically, our panelists discuss:
- What exactly AI can address in clinical efficiencies, drug discovery and drug development
- How AI can illuminate the “dark matter” of the human genome
- The impact AI can have on the mundane aspects of clinical research and where it’s on the cutting-edge
- What data has the great potential to move the needle soon in AI for IO?
For more information, visit immuno-oncology360.org.
Speakers
Andrew Allen, MD, PhD
President & CEO
Gritstone bio, Inc.
Alex Snyder, MD
Head of R&D
Generate Biomedicines
Sharon Benzeno, PhD, MBA
Chief Commercial Officer, Immune Medicine
Adaptive Biotechnologies
Ira Mellman, PhD
President of Research
Parker Institute for Cancer Immunotherapy (PICI)
Adeeb Rahman, PhD
CTO
Immunai
This content was created by The Conference Forum staff. The Fierce editorial team did not contribute to this work.